Generic drug competition: The pharmaceutical industry “gaming” controversy
dc.contributor.author | Hemphill, Thomas A. | |
dc.date.accessioned | 2020-01-13T15:02:59Z | |
dc.date.available | WITHHELD_12_MONTHS | |
dc.date.available | 2020-01-13T15:02:59Z | |
dc.date.issued | 2019-12 | |
dc.identifier.citation | Hemphill, Thomas A. (2019). "Generic drug competition: The pharmaceutical industry “gaming” controversy." Business and Society Review (4): 467-477. | |
dc.identifier.issn | 0045-3609 | |
dc.identifier.issn | 1467-8594 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/152498 | |
dc.description.abstract | Among American adults 20 years and older, 59 percent take at least one prescription drug on a regular basis. Unlike most branded drugs, which are generally drugs that have a trade name and are protected by a patent, off‐patent generic drugs make up approximately 90 percent of prescriptions annually filled in the United States; yet in 2017, generic drugs made up only 23 percent of total drug costs in the U.S. The U.S. Food and Drug Administration has taken the lead in encouraging increased competition in the nation’s prescription drug marketplace, most recently with its release of the agency’s Drug Competition Action Plan, but also with its regulatory guidance and enforcement efforts to eliminate “gaming” of the regulatory process by both branded and generic pharmaceutical manufacturers. Such “gaming” activities include “pay‐for‐delay” agreements involving financial compensation between branded and generic pharmaceutical manufacturers to forestall the emergence into the market of generic pharmaceuticals to compete against a formerly patent‐protected branded drug. A combination of new enabling legislation, federal judicial guidance, and agency regulatory activities show promise in encouraging increased competition in the prescription drug marketplace, with the American consumer the ultimate beneficiary of lower health care costs and improved overall personal health. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.publisher | Author | |
dc.subject.other | Federal Trade Commission | |
dc.subject.other | Food and Drug Administration | |
dc.subject.other | branded drugs | |
dc.subject.other | patents | |
dc.subject.other | pay-for-delays | |
dc.subject.other | generic drugs | |
dc.title | Generic drug competition: The pharmaceutical industry “gaming” controversy | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Business (General) | |
dc.subject.hlbtoplevel | Business and Economics | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/152498/1/basr12186_am.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/152498/2/basr12186.pdf | |
dc.identifier.doi | 10.1111/basr.12186 | |
dc.identifier.source | Business and Society Review | |
dc.identifier.citedreference | U.S. Food and Drug Administration. ( 2018c, January 3). Statement from FDA commissioner Scott Gottlieb, M.D., on new steps to facilitate efficient generic drug review to enhance competition, promote access and lower drug prices. Retrieved from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622252.htm | |
dc.identifier.citedreference | Gafney, A. ( 2018, August 21). Generic drug approvals are soaring at the FDA. PwC/United States. Retrieved from https://www.pwc.com/us/en/health-industries/healthcare-library/generic-drug-approvals-increasing.html | |
dc.identifier.citedreference | Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T., & Giovannucci, E. L. ( 2015, November 3). Trends in prescription drug use among adults in the United States from 1998–2012. Journal of the American Medical Association, 314 ( 17 ), 1818 – 1831. | |
dc.identifier.citedreference | Kroh, E. ( 2017, June 20). Actavis at 4: Pay‐for‐delay lawsuits receding. Law360. Retrieved from https://www.law360.com/articles/935490/actavis-at-4-pay-for-delay-lawsuits-receding | |
dc.identifier.citedreference | McCaughan, M. ( 2017, July 21). Patent Settlements. Prescription Drug Pricing, Health Policy Brief Series, No. 4, Health Affairs. Retrieved from https://www.healthaffairs.org/do/10.1377/hpb20170721.583967/full/healthpolicybrief_170.pdf | |
dc.identifier.citedreference | Noonan, K. E. ( 2016, February 29). FTC issues report on ANDA settlement agreements. Patent Docs. Retrieved from http://www.patentdocs.org/hatch-waxman/ | |
dc.identifier.citedreference | Sullivan, T. ( 2018a, May 4). FDA under pressure to speed up generic approvals. Policy & Medicine. Retrieved from https://www.policymed.com/2017/04/fda-under-pressure-to-speed-up-generic-approvals.html | |
dc.identifier.citedreference | Sullivan, T. ( 2018b, May 6). The Supreme Court and ‘pay for delay’: The potential impact on pharma. Policy & Medicine. Retrieved from https://www.policymed.com/2013/01/in-early-december-of-last-year-the-us-supreme-court-agreed-to-hear-a-case-to-decide-whether-agreements-between-brand-name.html | |
dc.identifier.citedreference | Sullivan, T. ( 2018c, May 6). Preserve access to affordable generics act: Congress proposes end to pay for delay. Policy & Medicine. Retrieved from https://www.policymed.com/2013/03/preserve-access-to-affordable-generics-act-congress-proposes-end-to-pay-for-delay.html | |
dc.identifier.citedreference | Syrop, J. ( 2018, July 2). FDA updates list of drugs without approved generic competitor. Center for Biosimilars, U.S. Food and Drug Administration. Retrieved from https://www.centerforbiosimilars.com/news/fda-updates-list-of-drugs-without-approved-generic-competition- | |
dc.identifier.citedreference | U.S. Department of Health and Human Services. ( 2016, January 27). Understanding recent trends in generic drug prices. Retrieved from https://aspe.hhs.gov/pdf-report/understanding-recent-trends-generic-drug-prices | |
dc.identifier.citedreference | U.S. Food and Drug Administration. ( 2017a, June 21). FDA working to lift barriers to generic drug competition. Retrieved from https://www.fda.gov/NewsEvents/Newsroom/FDAVoices/ucm612018.htm | |
dc.identifier.citedreference | U.S. Food and Drug Administration. ( 2017b, June 27). FDA tackles drug competition to improve patient access. Retrieved from https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm564725.htm | |
dc.identifier.citedreference | U.S. Food and Drug Administration. ( 2018a ). Who we are. Center for Drug Evaluation and Research, Office of Generic Drugs. Retrieved from https://www.fda.gov/aboutfda/centersoffices/officeof medicalproductsandtobacco/cder/ucm119100htm | |
dc.identifier.citedreference | U.S. Food and Drug Administration. ( 2018b ). Step 4: FDA drug review. Retrieved from https://fda.gov/ForPatients/Approvals/Drugs/ucm405570.htm | |
dc.identifier.citedreference | U.S. Food and Drug Administration. ( 2018d, January). 2017 Annual Report, Office of Generic Drugs. Washington, DC: Author. Retrieved from https://www.fda.gov/media/111198/download | |
dc.identifier.citedreference | U.S. Food and Drug Administration. ( 2018e, May 11). Statement from FDA commissioner Scott Gottlieb, M.D., on the Trump administration’s plan to Lower drug prices. Retrieved from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607495.htm | |
dc.identifier.citedreference | U.S. Food and Drug Administration. ( 2018f, July). Biosimilars action plan: Balancing innovation and competition. Washington, DC: Author. | |
dc.identifier.citedreference | U.S. Food and Drug Administration. ( 2018g, July 18). Remarks from FDA commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s Biosimilars Action Plan. Retrieved from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613881.htm | |
dc.identifier.citedreference | U.S. Food and Drug Administration. ( 2018h, July 19). Statement by FDA commissioner Scott Gottlieb, M.D., on the formation of a new work group to develop focused drug importation policy options to address access challenges related to certain sole‐source medicines with limited patient availability, but no blocking patents or exclusivities. Retrieved from https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm613931.htm | |
dc.identifier.citedreference | U.S. Food and Drug Administration. ( 2018i, October 2). Statement from FDA Commissioner Scott Gottleib, M.D., on new agency actions to further deter ‘gaming’ of the generic drug approval process by the use of citizen petitions. Retrieved from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622252.htm | |
dc.identifier.citedreference | U.S. Government Accountability Office. ( 2016, August). Generic drugs under Medicare: Part D generic drug prices declined overall, but some had extraordinary price increases. Retrieved from https://www.gao.gov/assets/680/679022.pdf | |
dc.identifier.citedreference | Association for Accessible Medicines. ( 2018, July 10). 2018 generic drug access & savings: Access in jeopardy. Washington, DC: Author. Retrieved from https://accessiblemeds.org/sites/default/files/2018_aam_generic_drug_access_and_savings_report.pdf | |
dc.identifier.citedreference | Berndt, E. R., Conti, R. M., & Murphy, S. J. ( 2018, May). The generic drug user fee amendments: An economic perspective. Journal of Law and Biosciences, 5 ( 1 ), 103 – 141. | |
dc.identifier.citedreference | Bloomberg Law. ( 2017 ). Side effects: The evolving law of ‘reverse payments’ and its impact on drug litigation. Retrieved from https://www.bna.com/uploadedFiles/BNA_V2/Legal/Pages/Custom_Trials/BLAW/24378%20BLW%20REP%20Points%20of%20Law%20Side%20Effects.pdf | |
dc.identifier.citedreference | Brennan, Z. ( 2016, November 1). Generic drug backlog at FDA: A dive into the confusing numbers. Regulatory Focus. Retrieved from https://www.raps.org/regulatory-focus%e2%84%a2/news-articles/2016/11/generic-drug-backlog-at-fda-a-dive-into-the-confusing-numbers | |
dc.identifier.citedreference | Congressional Budget Office. ( 1998, July). How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. Retrieved from http://www.cbo.gov/showdoc.cfm?index=655&sequence=0> | |
dc.identifier.citedreference | Express Scripts. ( 2017, August 17). Generics deliver value still. Retrieved from http://lab.express-scripts.com/lab/insights/drug-options/generics-deliver-value-still | |
dc.identifier.citedreference | Federal Trade Commission. ( 2010, January). Pay‐for‐delay: How drug company pay‐offs cost consumers billions, an FTC study. Washington, DC: Author. | |
dc.identifier.citedreference | Federal Trade Commission. ( 2016, January). Agreements filed with the Federal Trade Commission under the Medicare prescription drug improvement and Modernization Act of 2001: Overview of agreements filed in FT2014, A report of the Bureau of Competition. Retrieved from https://www.ftc.gov/system/files/documents/reports/agreements-filled-federal-trade-commission-under-medicare-prescription-drug-improvement/160113mmafy14rpt.pdf | |
dc.identifier.citedreference | Federal Trade Commission. ( 2018, May 24). Administrative law judge dismisses FTC antitrust complaint against generic pharmaceutical company Impax Laboratories. Retrieved from https://www.ftc.gov/news-events/press-releases/2018/05/administrative-law-judge-dismisses-ftc-antitrust-complaint | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.